Novo Nordisk makes the weight-loss drug Wegovy and trades under ticker NVO.
Wegovy is the brand name for semaglutide at a dose approved for chronic weight management in eligible patients. Novo Nordisk also markets Ozempic, a semaglutide product approved for treating type 2 diabetes, although the two products have different approved uses and dosing schedules.
Demand for diabetes and obesity medicines helped make Novo Nordisk one of Europe’s most valuable listed companies. Its market capitalization has been especially sensitive to clinical results, regulatory decisions, manufacturing capacity, and forecasts for future treatment demand.
Novo Nordisk originated in Denmark through the history of Novo Industri and Nordisk Gentofte. The companies merged in 1989, creating the modern business. Its shares trade in Copenhagen, while American depositary receipts use the ticker NVO.